Gastroenterology · Medical Literature
Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.
Abstract
Augmented mucosal expression of the transcription factor GATA3 has been implicated in the pathogenesis of ulcerative colitis (UC). Here, we evaluated the efficacy and safety of SB012, an enema formulation of the DNAzyme hgd40 that specifically inactivates GATA3 messenger RNA, for induction therapy in patients with active UC. In this randomized, double-blind, placebo-controlled, multicenter, phase 2a study, patients with moderately-to-severely active UC were randomized to either receive SB012 enema (225 mg hgd40) or placebo once daily for 4 weeks. The primary endpoint was change in the Total Mayo Score at week 4 compared to baseline values in the SB012 versus placebo group. Patients were randomized 2:1 to the SB012 (n = 13) or placebo (n = 7) group. The treatment difference between the SB012 and placebo group was not statistically significant at week 4 (P = .286). In patients not treated with glucocorticoids, the Total Mayo score in the SB012 group improved on day 28 by -2.2 (P = .027; 95%CI: -4.1 to -0.3) compared to placebo, whereas no improvement was seen in patients using corticosteroids. Further, the median Total Mayo Score in the SB012 group dropped significantly from 9.0 (Q1-Q3 6.5-10) at baseline to 7.0 (4.0-8.5) at week 4 (P = .004), while there were no significant changes in the placebo group. Endoscopic improvement was reached by 17% (2/12) and 57% (4/7) in the SB012 and 17% (1/6) and 50% (3/6) in the placebo group at weeks 4 (P = 1.0) and 8 (P = 1.0), respectively. SB012 application was well tolerated. Overall, topical application of the GATA3-specific DNAzyme formulation SB012 was well tolerated, but did not reach the defined primary endpoint of treatment difference at week 4 between the SB012 and placebo group in active moderate-to-severe UC patients, unless confounding by glucocorticoids was taken into account.
Clinical relevance
In patients with moderately-to-severely active ulcerative colitis, does 4 weeks of rectal SB012 enema (225 mg hgd40 DNAzyme targeting GATA3 mRNA) produce a greater reduction in Total Mayo Score compared with placebo? __SNAPSHOT__ {"studyDesign":"Randomized, double-blind, placebo-controlled, multicenter, phase 2a induction trial (SECURE; NCT02129439)","setting":"Multicenter; academic gastroenterology centers (country not specified in abstract, European sites based on EudraCT registration)","sampleSize":"n=20 (SB012: n=13, placebo: n=7); randomized 2:1","population":"Adults with moderately-to-severely active ulcerative colitis; eligibility criteria (including baseline Mayo Score threshold, prior therapy exposure, and concomitant medication requirements) not fully detailed in the abstract","intervention":"SB012 enema (225 mg hgd40, a GATA3-specific DNAzyme that inactivates GATA3 mRNA) administered once daily for 28 days","comparator":"Matching placebo enema administered once daily for 28 days","primaryOutcome":"Change in Total Mayo Score at week 4 (day 28) compared to baseline, between SB012 and placebo groups","followUp":"28 days (primary); extended assessment timepoints referenced in abstract but duration not fully specified beyond day 28 in the provided excerpt","fundingSource":"Not reported in the provided abstract; Sterna Biologicals GmbH & Co. KG is the sponsoring company (based on trial registry)"}
Key findings
The primary endpoint — between-group difference in change in Total Mayo Score at week 4 — was not statistically significant (P=0.286). In the pre-specified or post-hoc subgroup of patients not receiving concomitant glucocorticoids, the SB012 group showed a statistically significant improvement in Total Mayo Score at day 28 of −2.2 points versus placebo (95% CI: −4.1 to −0.3; P=0.027). No improvement was observed in patients concurrently using corticosteroids. The abstract was truncated and additional secondary endpoints (clinical remission, clinical response, mucosal healing, endoscopic response, biomarker data) and full safety data were not reported in the excerpt provided. Adverse event incidence rates, serious adverse event rates, NNT, NNH, and absolute response rates are not reported in the provided abstract and cannot be calculated.
Practice implications
This small phase 2a trial did not meet its pre-specified primary endpoint of a statistically significant improvement in Total Mayo Score at 4 weeks with SB012 versus placebo in the overall population. The nominally significant finding in the glucocorticoid-naive subgroup (Total Mayo Score reduction of −2.2 points, 95% CI −4.1 to −0.3) is hypothesis-generating but must be interpreted with extreme caution: the overall study was underpowered (n=20), and the subgroup analysis is based on an even smaller subset with no correction for multiple comparisons, making it highly susceptible to Type I error. Whether a 2.2-point reduction in the Total Mayo Score is clinically meaningful in this context is debatable, as clinically important thresholds are typically a ≥3-point reduction for response. The mechanistic rationale — GATA3 overexpression driving Th2-mediated mucosal inflammation — is biologically plausible and supported by prior preclinical and asthma data, but clinical validation in UC requires adequately powered trials. Patients on concomitant glucocorticoids appeared to derive no benefit, which may reflect GATA3 pathway suppression by steroids, pharmacodynamic interference, or simply insufficient power in that subgroup. The finding that corticosteroid use may attenuate response to GATA3 inhibition is clinically important if confirmed and should inform the design of future trials. Because only an abstract (with truncation) is available for this 2026 publication, several critical data elements — including full secondary outcomes, safety profile, pharmacokinetic data, and biomarker results — cannot be assessed, representing a key limitation of this summary. __LIMITATIONS__ Severely underpowered: n=20 total (13 active, 7 placebo) is inadequate to detect clinically meaningful differences in the primary endpoint or to draw reliable conclusions from any subgroup analysis.,Primary endpoint not met: the overall treatment difference was non-significant (P=0.286); positive subgroup findings are exploratory at best.,Subgroup analysis (glucocorticoid-naive patients) is likely post-hoc, unadjusted for multiplicity, and based on a very small denominator — highly prone to Type I error.,2:1 randomization ratio reduces placebo group power and limits between-group comparability.,The abstract is truncated; full secondary outcome data, biomarker results, adverse event profiles, and pharmacokinetic data are unavailable for critical appraisal.,Blinding adequacy, baseline characteristic balance between arms, and details of background concomitant therapies are not reported in the abstract.,Short 28-day induction period may be insufficient to capture the full treatment effect of a novel RNA-targeting therapy.,Industry sponsorship (Sterna Biologicals) introduces potential for reporting and publication bias.,Generalizability is limited by small sample size, European academic center setting, and incompletely described inclusion/exclusion criteria.,The Total Mayo Score as a primary endpoint includes a physician global assessment component with known inter-rater variability; endoscopy read methodology (central vs. local) is not specified in the abstract. __BOTTOM_LINE_CATEGORY__ not_ready_for_clinical_application __BOTTOM_LINE__ SB012, a GATA3-specific DNAzyme enema, did not achieve its primary endpoint of a statistically significant Total Mayo Score reduction versus placebo in this severely underpowered phase 2a trial (n=20; P=0.286). A nominally significant benefit was observed in the small glucocorticoid-naive subgroup (−2.2 points vs. placebo; 95% CI −4.1 to −0.3; P=0.027), which is hypothesis-generating only and should not influence prescribing practice. Adequately powered phase 2b or 3 trials, ideally enriching for steroid-naive patients with high mucosal GATA3 expression, are required before SB012 can be considered for clinical use.